Correction to: The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial: Loomba et al. (Hepatology, (2018), 67, 2, (549-559), 10.1002/hep.29514);The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial

Hepatology

Volumn 67, Issue 2, 2018, Pages 549-559

  Loomba, Rohit ^a   Lawitz, Eric ^b   Mantry, Parvez S ^c   Jayakumar, Saumya ^d   Caldwell, Stephen H ^e   Arnold, Hays ^f   Diehl, Anna Mae ^g   Djedjos, C Stephen ^h   Han, Ling ^h   Myers, Robert P ^h   Subramanian, G Mani ^h   McHutchison, John G ^h   Goodman, Zachary D ⁱ   Afdhal, Nezam H ^j   Charlton, Michael R ^k  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c Liver Instirtue at Methodist Dallas   (United States)

^d UNIVERSITY OF CALGARY   (Canada)

^e UNIVERSITY OF VIRGINIA   (United States)

^f Gastroenterology Consultants of San Antonio   (United States)

^g DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^h GILEAD SCIENCES   (United States)

ⁱ INOVA FAIRFAX HOSPITAL   (United States)

^j HARVARD MEDICAL SCHOOL   (United States)

^k INTERMOUNTAIN MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; APOPTOSIS SIGNAL REGULATING KINASE 1; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; COLLAGEN; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; SELONSERTIB; SIMTUZUMAB; TRIACYLGLYCEROL; MONOCLONAL ANTIBODY;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; APOPTOSIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACKACHE; BILIRUBIN BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; DRUG WITHDRAWAL; FATIGUE; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; HUMAN TISSUE; LIPOPROTEIN BLOOD LEVEL; LIVER BIOPSY; LIVER HISTOLOGY; LIVER NECROSIS; LIVER STIFFNESS; LONGITUDINAL STUDY; MAGNETIC RESONANCE ELASTOGRAPHY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NONALCOHOLIC FATTY LIVER; OPEN STUDY; PARESTHESIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SCHIZOPHRENIA; SINUSITIS; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; UPPER ABDOMINAL PAIN; CLINICAL TRIAL; DIAGNOSTIC IMAGING; ELASTOGRAPHY; LIVER CIRRHOSIS; MIDDLE AGED; PATHOLOGY;

ANTIBODIES, MONOCLONAL, HUMANIZED; ELASTICITY IMAGING TECHNIQUES; FEMALE; HUMANS; LIVER CIRRHOSIS; MALE; MAP KINASE KINASE KINASE 5; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE;

EID: 85037641328     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.29875     Document Type: Erratum

References (44)

1. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313-1321.
2. Younossi ZM, Stepanova M, Rafiq N, Makhlouf H, Younoszai Z, Agrawal R, et al. Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality. Hepatology 2011;53:1874-1882.
3. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012;55:2005-2023.
4. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011;34:274-285.
5. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease—meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016;64:73-84.
6. European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. Diabetologia 2016;59:1121-1140.
7. Ratziu V, Goodman Z, Sanyal A. Current efforts and trends in the treatment of NASH. J Hepatol 2015;62(1 Suppl.):S65-S75.
8. Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol 2013;10:686-690.
9. Torres DM, Harrison SA. Nonalcoholic fatty liver disease: fibrosis portends a worse prognosis. Hepatology 2015;61:1462-1464.
10. Charlton MR, Burns JM, Pedersen RA, Watt KD, Heimbach JK, Dierkhising RA. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology 2011;141:1249-1253.
11. Dulai PS, Singh S, Patel J, Soni M, Prokop LJ, Younossi Z, et al. Increased risk of mortality by fibrosis stage in non-alcoholic fatty liver disease: systematic review and meta-analysis. Hepatology 2017;65:1557-1565.
12. Ekstedt M, Hagström H, Nasr P, Fredrikson M, Stål P, Kechagias S, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 2015;61:1547-1554.
13. Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 2015;149:389-397.
14. Söderberg C, Stål P, Askling J, Glaumann H, Lindberg G, Marmur J, et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology 2010;51:595-602.
15. Bugianesi E, Marzocchi R, Villanova N, Marchesini G. Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH): treatment. Best Pract Res Clin Gastroenterol 2004;18:1105-1116.
16. Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Abdelmalek MF, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 2015;385:956-965.
17. Ratziu V. Novel pharmacotherapy options for NASH. Dig Dis Sci 2016;61:1398-1405.
18. Friedman SL, Bansal MB. Reversal of hepatic fibrosis—fact or fantasy? Hepatology 2006;43(2 Suppl. 1):S82-S88.
19. Perazzo H, Dufour JF. The therapeutic landscape of non-alcoholic steatohepatitis. Liver Int 2017;37:634-647.
20. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999;116:1413-1419.
21. Budas G, Karnik S, Jonnson T, Shafizadeh T, Watkins S, Breckenridge D, et al. Reduction of liver steatosis and fibrosis with an ASK1 inhibitor in a murine model of NASH is accomplished by improvements in cholesterol, bile acid and lipid metabolism [Abstract]. J Hepatol 2016;64(Suppl.):S170.
22. Yamamoto E, Dong YF, Kataoka K, Yamashita T, Tokutomi Y, Matsuba S, et al. Olmesartan prevents cardiovascular injury and hepatic steatosis in obesity and diabetes, accompanied by apoptosis signal regulating kinase-1 inhibition. Hypertension 2008;52:573-580.
23. Wang PX, Ji YX, Zhang XJ, Zhao LP, Yan ZZ, Zhang P, et al. Targeting CASP8 and FADD-like apoptosis regulator ameliorates nonalcoholic steatohepatitis in mice and nonhuman primates. Nat Med 2017;23:439-449.
24. Talal AH, Feron-Rigodon M, Madere J, Subramanian GM, Bornstein JD. Simtuzumab, an antifibrotic monoclonal antibody against lysyl oxidase-like 2 (LOXL2) enzyme, appears safe and well tolerated in patients with liver disease of diverse etiology [Abstract]. J Hepatol 2013;58(Suppl. 1):S532.
25. Ikenaga N, Liu SB, Peng ZW, Greenstein AE, French D, Smith V, et al. Dual combination therapy directed against lysyl oxidase-like 2 (LOXL2) and apoptosis signal–regulating kinase 1 (ASK1) potently inhibits fibrosis and portal hypertension in a new mouse model of PSC-like liver disease [Abstract]. Hepatology 2015;62(Suppl.):881A.
26. Sanyal A, Abdelmalek MF, Diehl AM, Caldwell S, Shiffman ML, Ghalib R, et al. Efficacy and safety of simtuzumab for the treatment of NASH with bridging fibrosis or cirrhosis: results of two phase 2b, dose-ranging, randomized, placebo-controlled trials [Abstract]. J Hepatol 2017;66(Suppl):S54.
27. Karanjia RN, Crossey MM, Cox IJ, Fye HK, Njie R, Goldin RD, et al. Hepatic steatosis and fibrosis: non-invasive assessment. World J Gastroenterol 2016;22:9880-9897.
28. Liu K, Xu W, Wong VWS. Serum biomarkers for nonalcoholic fatty liver disease: are we there yet? Hepatology 2017;65:8-11.
29. Loomba R, Sirlin CB, Ang B, Bettencourt R, Jain R, Salotti J, et al. Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial). Hepatology 2015;61:1239-1250.
30. Le TA, Chen J, Changchien C, Peterson MR, Kono Y, Patton H, et al. Effect of colesevelam on liver fat quantified by magnetic resonance in nonalcoholic steatohepatitis: a randomized controlled trial. Hepatology 2012;56:922-932.
31. Noureddin M, Lam J, Peterson MR, Middleton M, Hamilton G, Le TA, et al. Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials. Hepatology 2013;58:1930-1940.
32. Permutt Z, Le TA, Peterson MR, Seki E, Brenner DA, Sirlin C, et al. Correlation between liver histology and novel magnetic resonance imaging in adult patients with non-alcoholic fatty liver disease—MRI accurately quantifies hepatic steatosis in NAFLD. Aliment Pharmacol Ther 2012;36:22-29.
33. Cui J, Philo L, Nguyen P, Hofflich H, Hernandez C, Bettencourt R, et al. Sitagliptin vs. placebo for non-alcoholic fatty liver disease: a randomized controlled trial. J Hepatol 2016;65:369-376.
34. Dulai PS, Sirlin CB, Loomba R. MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: clinical trials to clinical practice. J Hepatol 2016;65:1006-1016.
35. Fontana RJ, Goodman ZD, Dienstag JL, Bonkovsky HL, Naishadham D, Sterling RK, et al. Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C. Hepatology 2008;47:789-798.
36. Reeder SB, Cruite I, Hamilton G, Sirlin CB. Quantitative assessment of liver fat with magnetic resonance imaging and spectroscopy. J Magn Reson Imaging 2011;34:729-749.
37. Bannas P, Kramer H, Hernando D. Quantitative magnetic resonance imaging of hepatic steatosis: validation in ex vivo human livers. Hepatology 2015;62:1444-1455.
38. Venkatesh SK, Yin M, Ehman RL. Magnetic resonance elastography of liver: technique, analysis, and clinical applications. J Magn Reson Imaging 2013;37:544-555.
39. Asrani SK, Talwalkar JA, Kamath PS, Shah VH, Saracino G, Jennings L, et al. Role of magnetic resonance elastography in compensated and decompensated liver disease. J Hepatol 2014;60:934-939.
40. Middleton MS, Lawitz E, Jayakumar S, Mantry P, Caldwell S, Diehl AM, et al. Hepatic proton density fat fraction correlates with histologic measures of steatosis and is responsive to changes in those measures in a multicenter nonalcoholic steatohepatitis clinical trial [Abstract]. J Hepatol 2017;66(Suppl.):S668.
41. Loomba R, Lawitz E, Ghalib R, Elkhashab M, Caldwell S, Abdelmalek M, et al. Longitudinal changes in liver stiffness by magnetic resonance elastography, liver fibrosis, and serum markers of fibrosis in a multicenter clinical trial in nonalcoholic steatohepatitis [Abstract]. J Hepatol 2017;66(Suppl.):S671.
42. Ichijo H, Nishida E, Irie K, ten Dijke P, Saitoh M, Moriguchi T, et al. Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways. Science 1997;275:90-94.
43. Saitoh M, Nishitoh H, Fujii M, Takeda K, Tobiume K, Sawada Y, et al. Mammalian thioredoxin is a direct inhibitor of apoptosis signal–regulating kinase (ASK) 1. EMBO J 1998;17:2596-2606.
44. Park CC, Nguyen P, Hernandez C, Bettencourt R, Ramirez K, Fortney L, et al. Magnetic resonance elastography vs transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy-proven nonalcoholic fatty liver disease. Gastroenterology 2017;152:598-607.